全文获取类型
收费全文 | 3418356篇 |
免费 | 293150篇 |
国内免费 | 13781篇 |
专业分类
耳鼻咽喉 | 48281篇 |
儿科学 | 110621篇 |
妇产科学 | 90586篇 |
基础医学 | 542976篇 |
口腔科学 | 93421篇 |
临床医学 | 303533篇 |
内科学 | 602150篇 |
皮肤病学 | 91412篇 |
神经病学 | 291117篇 |
特种医学 | 136704篇 |
外国民族医学 | 391篇 |
外科学 | 538040篇 |
综合类 | 102387篇 |
现状与发展 | 23篇 |
一般理论 | 2209篇 |
预防医学 | 282946篇 |
眼科学 | 78832篇 |
药学 | 239032篇 |
18篇 | |
中国医学 | 9669篇 |
肿瘤学 | 160939篇 |
出版年
2021年 | 53414篇 |
2020年 | 35159篇 |
2019年 | 58226篇 |
2018年 | 71444篇 |
2017年 | 54041篇 |
2016年 | 59692篇 |
2015年 | 73946篇 |
2014年 | 108321篇 |
2013年 | 173732篇 |
2012年 | 90812篇 |
2011年 | 91063篇 |
2010年 | 116730篇 |
2009年 | 121315篇 |
2008年 | 79163篇 |
2007年 | 82638篇 |
2006年 | 93480篇 |
2005年 | 89374篇 |
2004年 | 91043篇 |
2003年 | 82382篇 |
2002年 | 72776篇 |
2001年 | 104548篇 |
2000年 | 97264篇 |
1999年 | 97520篇 |
1998年 | 65413篇 |
1997年 | 62746篇 |
1996年 | 55105篇 |
1995年 | 55876篇 |
1994年 | 50262篇 |
1993年 | 46735篇 |
1992年 | 69250篇 |
1991年 | 66782篇 |
1990年 | 64093篇 |
1989年 | 63214篇 |
1988年 | 59129篇 |
1987年 | 57635篇 |
1986年 | 54973篇 |
1985年 | 54967篇 |
1984年 | 49408篇 |
1983年 | 45338篇 |
1982年 | 41763篇 |
1981年 | 39244篇 |
1980年 | 36928篇 |
1979年 | 41487篇 |
1978年 | 36154篇 |
1977年 | 33011篇 |
1976年 | 30420篇 |
1975年 | 29729篇 |
1974年 | 31036篇 |
1973年 | 29886篇 |
1972年 | 28250篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
151.
Sarina A. Piha-Paul Do-Youn Oh Makoto Ueno David Malka Hyun Cheol Chung Adnan Nagrial Robin K. Kelley Willeke Ros Antoine Italiano Kazuhiko Nakagawa Hope S. Rugo Filippo de Braud Andrea Iolanda Varga Aaron Hansen Hui Wang Suba Krishnan Kevin G. Norwood Toshihiko Doi 《International journal of cancer. Journal international du cancer》2020,147(8):2190-2198
We present data from patients with advanced biliary tract cancer (BTC) receiving pembrolizumab in the KEYNOTE-158 (NCT02628067; phase 2) and KEYNOTE-028 (NCT02054806; phase 1b) studies. Eligible patients aged ≥18 years from both studies had histologically/cytologically confirmed incurable BTC that progressed after standard treatment regimen(s), measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Eastern Cooperative Oncology Group performance status 0/1, and no prior immunotherapy. Programmed death ligand 1 (PD-L1)-positive tumors were required for eligibility in KEYNOTE-028 only. Patients received pembrolizumab 200 mg every three weeks (KEYNOTE-158) or 10 mg/kg every two weeks (KEYNOTE-028) for ≤2 years. Primary efficacy endpoint was objective response rate (ORR) by RECIST v1.1. Response assessed by independent central review is reported. KEYNOTE-158 enrolled 104 patients and KEYNOTE-028 enrolled 24 patients. Median (range) follow-up was 7.5 months (0.6-34.3) in KEYNOTE-158 and 5.7 months (0.6-55.4) in KEYNOTE-028. In KEYNOTE-158, ORR was 5.8% (6/104; 95% CI, 2.1%-12.1%); median duration of response (DOR) was not reached (NR) (range, 6.2-26.6+ months). Median (95% CI) OS and PFS were 7.4 (5.5-9.6) and 2.0 (1.9-2.1) months. Among PD-L1-expressers (n = 61) and PD-L1-nonexpressers (n = 34), respectively, ORR was 6.6% (4/61) and 2.9% (1/34). In KEYNOTE-028, ORR was 13.0% (3/23; 95% CI, 2.8%-33.6%); median DOR was NR (range, 21.5-53.2+ months). Median (95% CI) OS and PFS were 5.7 (3.1-9.8) and 1.8 (1.4-3.1) months. Grade 3 to 5 treatment-related adverse events occurred in 13.5% of patients in KEYNOTE-158 (no grade 4; grade 5 renal failure, n = 1) and 16.7% in KEYNOTE-028 (no grade 4/5). In summary, pembrolizumab provides durable antitumor activity in 6% to 13% of patients with advanced BTC, regardless of PD-L1 expression, and has manageable toxicity. 相似文献
152.
153.
154.
Balta Sabah Emirtekin Emrah Kircaburun Kagan Griffiths Mark D. 《International journal of mental health and addiction》2020,18(3):628-639
International Journal of Mental Health and Addiction - One of the relatively new negative consequences of smartphone use is “phubbing” (snubbing someone while an individual checks their... 相似文献
155.
156.
Samir Gupta MD MDCS AGAF Balambal Bharti MBBS MPH PhD Dennis J. Ahnen MD Daniel D. Buchanan PhD Iona C. Cheng PhD MPH Michelle Cotterchio PhD Jane C. Figueiredo PhD Steven J. Gallinger MD MSc Robert W. Haile DrPH MPH Mark A. Jenkins PhD Noralane M. Lindor MD Finlay A. Macrae MD AGAF Loïc Le Marchand MD PhD Polly A. Newcomb PhD MPH Stephen N. Thibodeau PhD Aung Ko Win MBBS MPH PhD Maria Elena Martinez PhD 《Cancer》2020,126(13):3013-3020
157.
Krishna S. Iyer 《Platelets》2020,31(4):474-482
Abstract Platelets are small, anucleated effector cells that play an important role in linking the hemostatic and inflammatory processes in the body. Platelet function is known to be altered under various inflammatory conditions including aging. A gain in platelet function during aging can increase the risk of thrombotic events, such as stroke and acute myocardial infarction. Anti-platelet therapy is designed to reduce risk of serious cerebrovascular and cardiovascular events, but the adverse consequences of therapy, such as risk for bleeding increases with aging as well. Age-associated comorbidities such as obesity, diabetes, and hyperlipidemia also contribute to increased platelet activity and thus can enhance the risk of thrombosis. Therefore, identification of unique mechanisms of platelet dysfunction in aging and in age-associated comorbidities is warranted to design novel antiplatelet drugs. This review outlines some of the current areas of research on aging-related mechanisms of platelet hyperactivity and addresses the clinical urgency for designing anti-platelet therapies toward novel molecular targets in the aging population. 相似文献
158.
Aliyah Hussein Kiran Sran Imran Ali Janine Woellner Helen Wilcox Stephen D. Marks Helen Jones Chris Callaghan 《Pediatric transplantation》2020,24(4)
Transplant ureteric stent insertion reduces the incidence of MUCs, but it is not known whether routine PSRGU is needed to detect unmasked MUCs. This study evaluated whether routine PSRGU in the pRTR is a useful tool to identify MUCs before they become clinically apparent. A retrospective analysis was undertaken of the clinical outcomes following elective stent removal from pediatric kidney‐only transplant recipients at two London centers between 2012 and 2016. Our policy was to perform PSRGU either routinely or urgently if there were concerning symptoms or biochemical evidence of renal allograft dysfunction. Elective stent removal was performed in 86% (97 of 113 pRTR), and 75 (77%) of whom had routine PSRGU at a median (IQR) of 6 (2‐8) days after stent removal. There were changes to management in 3 (4%) of pRTR with PSRGU identifying no MUC. Nineteen patients (25%) had urgent PSRGU, most commonly due to renal allograft dysfunction, at a median (IQR) of 5.5 (2.7‐12.3) days after stent removal. Of these, two pRTR required ureteric intervention. For our current practice of removing transplant stents at 4‐6 weeks post‐transplantation, our study has found no evidence to support routine PSRGU after elective stent removal. 相似文献
159.
Candayan Ayşe Yunisova Gulshan Çakar Arman Durmuş Hacer Başak A. Nazlı Parman Yeşim Battaloğlu Esra 《Neurogenetics》2020,21(1):73-78
neurogenetics - Charcot-Marie-Tooth (CMT) disease is the most common inherited neuropathy with a prevalence of 1 in 2500 individuals worldwide. Here, we report three Turkish siblings from... 相似文献
160.
Key Jana Maletzko Antonia Kohli Aneesha Gispert Suzana Torres-Odio Sylvia Wittig Ilka Heidler Juliana Bárcena Clea López-Otín Carlos Lei Yuanjiu West A. Phillip Münch Christian Auburger Georg 《Neurogenetics》2020,21(3):187-203
neurogenetics - Human RNF213, which encodes the protein mysterin, is a known susceptibility gene for moyamoya disease (MMD), a cerebrovascular condition with occlusive lesions and compensatory... 相似文献